TargetMol
Cetirizine dihydrochloride is an effective second-generation histamine H1 antagonist that is potent in the therapy of allergic rhinitis, confirmed urticaria, and pollen-induced asthma. Unlike other conventional antihistamines, it does not cause side effects of drowsiness or anticholinergic.
More Information
Supplier Page
TargetMol
TargetMol
TargetMol
Balofloxacin
100 mg
| Purity Not Available
TargetMol
Balofloxacin, a quinolone antibiotic, can inhibit the synthesis of bacterial DNA by interfering with the DNA gyrase.
More Information
Supplier Page
GSK-J4
100 mg
| 97.07%
TargetMol
GSK-J4 (GSK J4 HCl) is a potent H3K27me3 demethylase inhibitor, with IC50s of 8.6 μM and 6.6 μM towards KDM6B and KDM6A respectively. It is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM in a cell-free assay and inactive against a panel of demethylases of the […]
More Information
Supplier Page
TargetMol
Galunisertib is an orally available inhibitor of TGFβRI kinase (IC50: 56 nM) with potential antineoplastic activity.
More Information
Supplier Page
TargetMol
Galunisertib is an orally available inhibitor of TGFβRI kinase (IC50: 56 nM) with potential antineoplastic activity.
More Information
Supplier Page
GSK-J4
5 mg
| 97.07%
TargetMol
GSK-J4 (GSK J4 HCl) is a potent H3K27me3 demethylase inhibitor, with IC50s of 8.6 μM and 6.6 μM towards KDM6B and KDM6A respectively. It is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM in a cell-free assay and inactive against a panel of demethylases of the […]
More Information
Supplier Page
GSK-J4
50 mg
| 97.07%
TargetMol
GSK-J4 (GSK J4 HCl) is a potent H3K27me3 demethylase inhibitor, with IC50s of 8.6 μM and 6.6 μM towards KDM6B and KDM6A respectively. It is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM in a cell-free assay and inactive against a panel of demethylases of the […]
More Information
Supplier Page